Aratana Therapeutics, Inc.
PETX
PETX was delisted on the 17th of July, 2019.
103 hedge funds and large institutions have $200M invested in Aratana Therapeutics, Inc. in 2019 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 33 increasing their positions, 20 reducing their positions, and 32 closing their positions.
1,479% more call options, than puts
Call options by funds: $442K | Put options by funds: $28K
74% more capital invested
Capital invested by funds: $115M → $200M (+$85.1M)
65% more repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 20
3% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 32
1% less funds holding
Funds holding: 104 → 103 (-1)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Tudor Investment Corp
Stamford,
Connecticut
|
+$14M |
| 2 |
WIC
Water Island Capital
New York
|
+$12.8M |
| 3 |
Man Group
London,
United Kingdom
|
+$12.3M |
| 4 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
+$10.8M |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
+$4.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
-$8.7M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$5.73M |
| 3 |
JG
Jefferies Group
New York
|
-$5.4M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.95M |
| 5 |
GPGA
Grandeur Peak Global Advisors
Salt Lake City,
Utah
|
-$3.93M |
PETX Hedge Fund Activity: Q2 2019 in Review
103 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q2 2019, worth a combined $200M — up 74% from $115M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new PETX positions and 32 closed out — a net gain of 1 holder — while 33 added to existing stakes and 20 trimmed.
The largest buyer was Tudor Investment Corp, adding an estimated $14M. The largest seller was Engaged Capital, exiting entirely with an estimated $8.7M sold.
- 103 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q2 2019, down from 104 in Q1 2019.
- Funds reported $200M of Aratana Therapeutics, Inc. stock for Q2 2019, up 74% quarter-over-quarter.
- 33 funds opened new Aratana Therapeutics, Inc. positions in Q2 2019 and 32 closed out, a net change of +1 holder.
- The largest Aratana Therapeutics, Inc. buyer in Q2 2019 was Tudor Investment Corp, an estimated $14M added.
- The largest Aratana Therapeutics, Inc. seller in Q2 2019 was Engaged Capital, an estimated $8.7M sold.
Based on aggregated 13F filings for Q2 2019.